Search Technologies

Researchers at the National Cancer Institute (NCI) have developed an improved class of heptamethine cyanine fluorophore dyes useful for imaging applications in the near-IR range (750-850 nm). A new chemical reaction has been developed that provides easy access to novel molecules with improved properties. Specifically, the dyes display greater resistance to thiol nucleophiles, and are more robust while maintaining excellent optical properties. The dyes have been successfully employed in various in vivo imaging applications and in vitro labeling and microscopy applications. The NCI seek co-development or licensees to develop them as targetable agents for optical-guided surgical interventions.

Scientists at the National Cancer Institute (NCI) have developed a novel delivery platform in which the scaffold of an anionic hydrogel (AcVES3) can be attenuated to deliver therapeutic small molecules, peptides, proteins, nanoparticles, or whole cells. The NCI seeks collaborators and licensees for the development of this technology in various clinical and laboratory applications.

Surgery specialists from Johns Hopkins University, in collaboration with researchers at the National Cancer Institute (NCI), developed peptide hydrogel compositions and methods to suture blood vessels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks co-development research collaborations for further development of this technology.

The National Eye Institute seeks research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method; (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.

The National Cancer Institute (NCI) seeks licensees for an SLC46A3 knockout mouse line. SLC46A3 is a solute carrier of the Major Facilitator Superfamily (MFS) and is thought to have roles in multiple diseases including nonalcoholic fatty liver disease, liver cancer and obesity.

Researchers at the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have developed novel heterocyclic scaffold-based inhibitors of the polo-box domain (PBD) of Polo-like kinase 1 (Plk1). These compounds effectively arrest mitotic progression and cell proliferation in cell-based assays. The National Institutes of Health (NIH) seeks licensing and/or co-development research collaborations to further develop these inhibitors for the treatment of cancer.

The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for oxynitidine derivatives as new topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors for treating cancer. These TOP1 and TDP1 inhibitors administered in combination display increased anti-tumor potency.

Researchers at the National Cancer Institute (NCI) developed orthotopic allograft models for pancreatic cancer that utilize cells or tumor fragments implanted into the cancer-free pancreata of recipient immunocompetent mice. NCI seeks licensees to commercialize this invention.

Researchers at the National Cancer Institute (NCI) developed a novel biophysical technique to purify extracellular vesicles (EVs) from contaminants such as proteins and unbound labels. The NCI seeks licensees and/or co-development research collaborations to further advance this technology for EV-based biomarkers and therapeutics to treat a wide range of diseases.